Drugs / CAR.70/IL15-transduced CB-derived NK cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05703854 | Mar 2023 → Sep 2027 expected | mesothelioma, osteosarcoma, renal cell carcinoma | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CAR.70/IL15-transduced CB-derived NK cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05703854 ↗ |
| Route | Intravenous | “Given by IV (vein)” NCT05703854 ↗ |